Can tricuspid regurgitation cause atrial fibrillation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Tricuspid Regurgitation Cause Atrial Fibrillation?

The relationship between tricuspid regurgitation (TR) and atrial fibrillation (AF) is bidirectional—AF more commonly causes TR through annular remodeling, but TR can also contribute to AF development through right atrial enlargement and dysfunction.

The Predominant Direction: AF Causes TR

The guideline evidence clearly establishes that AF-induced annular remodeling is a major determinant of secondary TR 1. This mechanism is so well-recognized that guidelines specifically address "atrial functional tricuspid regurgitation" as a distinct entity, recommending TV repair with annuloplasty (Class IIb) in AF patients with progressive RV dysfunction and/or dilation despite guideline-directed medical therapy 1.

The 2020 ACC/AHA guidelines note that severe symptomatic isolated TR is "commonly associated with device leads and atrial fibrillation" 2, reinforcing AF as a primary driver of TR rather than the reverse.

The Reverse Relationship: TR Can Contribute to AF

While less emphasized in guidelines, recent research demonstrates that TR is independently associated with AF development:

  • In acute ischemic stroke patients, TR was strongly associated with AF (adjusted OR 4.87) regardless of severity (mild TR: aOR 4.57; moderate-to-severe TR: aOR 7.05) 3
  • Among patients without known AF at admission, TR was associated with newly diagnosed AF during hospitalization and 1-year follow-up (aOR 2.68) 3
  • Post-TAVR registry data shows AF/AFL independently predicted TR progression (sub-distribution hazard ratio 1.82), but this primarily reflects AF worsening existing TR 4

The Mechanistic Explanation

The bidirectional relationship operates through these pathways:

AF → TR pathway (dominant):

  • AF causes right atrial enlargement and tricuspid annular dilation
  • Loss of atrial contraction reduces valve coaptation
  • Persistent AF duration directly correlates with TR severity 5, 6

TR → AF pathway (less common):

  • Chronic TR causes right atrial stretch and enlargement
  • Right atrial remodeling creates substrate for atrial arrhythmias
  • Elevated left atrial pressure in AF patients with TR further promotes right heart remodeling 6

Clinical Implications

When evaluating patients with both TR and AF:

  • Assume AF is the primary driver unless evidence suggests primary valvular pathology (trauma, congenital dysplasia, endocarditis) 7
  • Persistent AF duration, female sex, age ≥65 years, and heart failure are key predictors of significant TR in AF patients 5
  • Elevated left atrial systolic pressure, mitral regurgitation, and AF duration are independent predictors of significant TR 6
  • Consider 3D-transesophageal echocardiography when TR severity seems disproportionate to AF burden, as structural valve abnormalities may be missed on standard TTE 7

Bottom Line

While TR can theoretically contribute to AF through right atrial remodeling, the overwhelming clinical reality is that AF causes TR through annular dilation. The guideline focus on "atrial functional TR" and the consistent research showing AF as a predictor of TR progression—rather than the reverse—confirms this directionality. When both conditions coexist, treat the AF aggressively with rhythm control and address TR surgically when indicated by symptoms, RV dysfunction, or during concomitant left-sided valve surgery 1, 2.

Related Questions

In a patient with a 2D echocardiogram showing normal left atrium and left ventricle, no mitral regurgitation, grade I left ventricular systolic dysfunction, severe tricuspid regurgitation, severe pulmonary arterial hypertension with a D‑shaped interventricular septum and pulmonary artery systolic pressure of 84 mmHg, and a hemoglobin of 6.8 g/dL, should a component of left‑heart disease or a hyperdynamic circulation be considered?
In a 60-year-old male with incidentally detected atrial fibrillation, CHA2DS2‑VASc (0) score, low TSH, mild left ventricular hypertrophy, and trace mitral and tricuspid regurgitation, does he require anticoagulation and what cardiac workup (ECG, ambulatory rhythm monitoring, repeat echocardiogram) is indicated?
What is the appropriate management for a patient with dilated right ventricle and right atrium, normal tricuspid annular plane systolic excursion (TAPSE), and atrial fibrillation?
In a patient who had a transthoracic echocardiogram six months ago and now presents with new‑onset atrial fibrillation, should a repeat echocardiogram be performed?
If a patient can lift or carry the maximum required weight in pounds, does this necessitate a referral to physical therapy for a functional capacity assessment?
What are the indications, dosing guidelines, side effects, monitoring parameters, and contraindications for carbamazepine?
What other causes could explain chronic pelvic pain in a patient with normal imaging studies and a remote history of abdominal mesh placement?
In a 23-year-old woman with prior Tetralogy of Fallot repair presenting with dyspnea, palpitations, a single S1 and a grade 2/4 early diastolic decrescendo murmur that intensifies with inspiration at the left sternal border, what is the most likely diagnosis?
What is the recommended dose and administration route for the live attenuated measles‑mumps‑rubella (MMR) vaccine (0.5 mL subcutaneously, containing 1,000–12,500 TCID₅₀)?
What is the recommended intravenous morphine dosing regimen for an adult with acute coronary syndrome requiring analgesia, including initial bolus, repeat dosing, continuous infusion rates, and maximum dose limits?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.